---
document_datetime: 2024-08-22 10:34:43
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/rystiggo-epar-all-authorised-presentations_en.pdf
document_name: rystiggo-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.9034865
conversion_datetime: 2025-12-24 06:22:48.787964
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size   |
|------------------|-------------------|------------|------------------------|---------------------------|-----------------------|---------------------------|-------------|
| EU/1/23/1780/001 | Rystiggo          | 140 mg/ml  | Solution for injection | Subcutaneous use          | vial (glass)          | 2 ml                      | 1 vial      |
| EU/1/23/1780/002 | Rystiggo          | 140 mg/ml  | Solution for injection | Subcutaneous use          | vial (glass)          | 3 ml                      | 1 vial      |
| EU/1/23/1780/003 | Rystiggo          | 140 mg/ml  | Solution for injection | Subcutaneous use          | vial (glass)          | 4 ml                      | 1 vial      |
| EU/1/23/1780/004 | Rystiggo          | 140 mg/ml  | Solution for injection | Subcutaneous use          | vial (glass)          | 6 ml                      | 1 vial      |